Vitamin K2 Blood Pressure Randomized Trial: What the Evidence Says

Quick Answer

Vitamin K2 Blood Pressure Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 randomized trial, 1 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Over the past four decades, the prevalence of obesity among young adults has increased substantially, rising from 5.5% to 32.6%. [Olivares-Ochoa Xochitl Citlalli (2026); evidence level 2]
• Prolonged exposure to unhealthy behaviors-such as poor diet and sedentary lifestyle-combined with environmental and genetic factors during this critical period, may substantially increase the risk of developing obesity. [Olivares-Ochoa Xochitl Citlalli (2026); evidence level 2]
• Vitamin D deficiency has been consistently associated with adverse outcomes, including increased susceptibility to cancers, diabetes, hypertension, and cardiovascular disease. [D’Elia Saverio (2025); evidence level 3]
• Epidemiological studies further indicate that populations in regions with higher sun exposure exhibit lower prevalence of deficiency and reduced mortality from chronic disease. [D’Elia Saverio (2025); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For vitamin k2 blood pressure randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Olivares-Ochoa Xochitl Citlalli (2026). Vitamin K2 Supplementation Reduces Cardiometabolic Risk Factors in Young Adults with Overweight and Obesity—A Randomized Placebo-Controlled Trial. DOI: 10.3390/biomedicines14051011. PMCID: PMC13204484. PMID: 42193338. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13204484/
• D’Elia Saverio (2025). Modulation of Cardiometabolic Risk by Vitamin D and K2: Simple Supplementation or Real Drug? Uncovering the Pharmacological Properties. DOI: 10.3390/ijms27010298. PMCID: PMC12785717. PMID: 41516172. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12785717/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.